The published version of our article contains some errors in Figures 3, 5 that do not affect the final findings or conclusions, and we hereby publish the corrections. We sincerely apologize for these unintentional errors, which arose from carelessness during data acquisition and image preparation. The new versions of Figures 3 and 5 are shown below.
Figure 3.
Representative western blot analysis showing the ability of the four PI3K/mTOR pathway inhibitors to modify the phosphorylation of proteins involved in the pathways transduction in eight NSCLC cell lines. Proteins were extracted 0, 6 and 24 hours after treatment start. Cells were treated with a concentration corresponding to the IC50 of the drug determined in the most sensitive cell line. The different cell lines were run on different gels.
Figure 5.
Representative western blot analysis showing the ability of MEK-162 and SCH772984 to modify the phosphorylation of ERK and other proteins as indicated in the figure in eight cell lines 6 and 24 hours after treatment start. Cells were treated with a concentration corresponding to the IC50 of the drug determined in the most sensitive cell line. The different cell lines were run on different gels.